272 related articles for article (PubMed ID: 31174993)
21. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
22. Gastric bypass versus sleeve gastrectomy in patients with type 2 diabetes (Oseberg): a single-centre, triple-blind, randomised controlled trial.
Hofsø D; Fatima F; Borgeraas H; Birkeland KI; Gulseth HL; Hertel JK; Johnson LK; Lindberg M; Nordstrand N; Cvancarova Småstuen M; Stefanovski D; Svanevik M; Gretland Valderhaug T; Sandbu R; Hjelmesæth J
Lancet Diabetes Endocrinol; 2019 Dec; 7(12):912-924. PubMed ID: 31678062
[TBL] [Abstract][Full Text] [Related]
23. Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial.
Dungan KM; Povedano ST; Forst T; González JG; Atisso C; Sealls W; Fahrbach JL
Lancet; 2014 Oct; 384(9951):1349-57. PubMed ID: 25018121
[TBL] [Abstract][Full Text] [Related]
24. MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study.
Ambery P; Parker VE; Stumvoll M; Posch MG; Heise T; Plum-Moerschel L; Tsai LF; Robertson D; Jain M; Petrone M; Rondinone C; Hirshberg B; Jermutus L
Lancet; 2018 Jun; 391(10140):2607-2618. PubMed ID: 29945727
[TBL] [Abstract][Full Text] [Related]
25. Effect of Liraglutide on Arterial Inflammation Assessed as [
Ripa RS; Zobel EH; von Scholten BJ; Jensen JK; Binderup T; Diaz LJ; Curovic VR; Hansen TW; Rossing P; Kjaer A
Circ Cardiovasc Imaging; 2021 Jul; 14(7):e012174. PubMed ID: 34187185
[TBL] [Abstract][Full Text] [Related]
26. Early metabolomic, lipid and lipoprotein changes in response to medical and surgical therapeutic approaches to obesity.
Angelidi AM; Kokkinos A; Sanoudou D; Connelly MA; Alexandrou A; Mingrone G; Mantzoros CS
Metabolism; 2023 Jan; 138():155346. PubMed ID: 36375643
[TBL] [Abstract][Full Text] [Related]
27. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial.
Garvey WT; Frias JP; Jastreboff AM; le Roux CW; Sattar N; Aizenberg D; Mao H; Zhang S; Ahmad NN; Bunck MC; Benabbad I; Zhang XM;
Lancet; 2023 Aug; 402(10402):613-626. PubMed ID: 37385275
[TBL] [Abstract][Full Text] [Related]
28. Dose-response effects on HbA
Blüher M; Rosenstock J; Hoefler J; Manuel R; Hennige AM
Diabetologia; 2024 Mar; 67(3):470-482. PubMed ID: 38095657
[TBL] [Abstract][Full Text] [Related]
29. Durability of insulin degludec plus liraglutide versus insulin glargine U100 as initial injectable therapy in type 2 diabetes (DUAL VIII): a multicentre, open-label, phase 3b, randomised controlled trial.
Aroda VR; González-Galvez G; Grøn R; Halladin N; Haluzík M; Jermendy G; Kok A; Őrsy P; Sabbah M; Sesti G; Silver R
Lancet Diabetes Endocrinol; 2019 Aug; 7(8):596-605. PubMed ID: 31189519
[TBL] [Abstract][Full Text] [Related]
30. Ursodeoxycholic acid for the prevention of symptomatic gallstone disease after bariatric surgery (UPGRADE): a multicentre, double-blind, randomised, placebo-controlled superiority trial.
Haal S; Guman MSS; Boerlage TCC; Acherman YIZ; de Brauw LM; Bruin S; de Castro SMM; van Hooft JE; van de Laar AWJM; Moes DE; Schouten M; Schouten R; van Soest EJ; van Veen RN; de Vries CEE; Fockens P; Dijkgraaf MGW; Gerdes VEA; Voermans RP
Lancet Gastroenterol Hepatol; 2021 Dec; 6(12):993-1001. PubMed ID: 34715031
[TBL] [Abstract][Full Text] [Related]
31. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
[TBL] [Abstract][Full Text] [Related]
32. Liraglutide reduces hyperglycaemia and body weight in overweight, dysregulated insulin-pump-treated patients with type 1 diabetes: The Lira Pump trial-a randomized, double-blinded, placebo-controlled trial.
Dejgaard TF; Schmidt S; Frandsen CS; Vistisen D; Madsbad S; Andersen HU; Nørgaard K
Diabetes Obes Metab; 2020 Apr; 22(4):492-500. PubMed ID: 31696598
[TBL] [Abstract][Full Text] [Related]
33. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial.
Lau DCW; Erichsen L; Francisco AM; Satylganova A; le Roux CW; McGowan B; Pedersen SD; Pietiläinen KH; Rubino D; Batterham RL
Lancet; 2021 Dec; 398(10317):2160-2172. PubMed ID: 34798060
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial.
Charbonnel B; Steinberg H; Eymard E; Xu L; Thakkar P; Prabhu V; Davies MJ; Engel SS
Diabetologia; 2013 Jul; 56(7):1503-11. PubMed ID: 23604551
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.
O'Neil PM; Birkenfeld AL; McGowan B; Mosenzon O; Pedersen SD; Wharton S; Carson CG; Jepsen CH; Kabisch M; Wilding JPH
Lancet; 2018 Aug; 392(10148):637-649. PubMed ID: 30122305
[TBL] [Abstract][Full Text] [Related]
36. Efficacy and safety of meal-time administration of short-acting exenatide for glycaemic control in type 1 diabetes (MAG1C): a randomised, double-blind, placebo-controlled trial.
Johansen NJ; Dejgaard TF; Lund A; Schlüntz C; Frandsen CS; Forman JL; Wewer Albrechtsen NJ; Holst JJ; Pedersen-Bjergaard U; Madsbad S; Vilsbøll T; Andersen HU; Knop FK
Lancet Diabetes Endocrinol; 2020 Apr; 8(4):313-324. PubMed ID: 32135138
[TBL] [Abstract][Full Text] [Related]
37. Twelve-Week Treatment With Liraglutide as Add-on to Insulin in Normal-Weight Patients With Poorly Controlled Type 1 Diabetes: A Randomized, Placebo-Controlled, Double-Blind Parallel Study.
Frandsen CS; Dejgaard TF; Holst JJ; Andersen HU; Thorsteinsson B; Madsbad S
Diabetes Care; 2015 Dec; 38(12):2250-7. PubMed ID: 26486191
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo-controlled trial.
Ahmann A; Rodbard HW; Rosenstock J; Lahtela JT; de Loredo L; Tornøe K; Boopalan A; Nauck MA;
Diabetes Obes Metab; 2015 Nov; 17(11):1056-64. PubMed ID: 26179619
[TBL] [Abstract][Full Text] [Related]
39. Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial.
Kadowaki T; Isendahl J; Khalid U; Lee SY; Nishida T; Ogawa W; Tobe K; Yamauchi T; Lim S;
Lancet Diabetes Endocrinol; 2022 Mar; 10(3):193-206. PubMed ID: 35131037
[TBL] [Abstract][Full Text] [Related]
40. Improved glycaemic control with minimal hypoglycaemia and no weight change with the once-daily human glucagon-like peptide-1 analogue liraglutide as add-on to sulphonylurea in Japanese patients with type 2 diabetes.
Kaku K; Rasmussen MF; Clauson P; Seino Y
Diabetes Obes Metab; 2010 Apr; 12(4):341-7. PubMed ID: 20380655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
